Onyx Shifts Priorities Away From JAK Inhibitors, Puts More Emphasis on Carfilzomib

Onyx Pharmaceuticals opted out of a licensing agreement with Singapore's S*Bio for JAK2 inhibitors, while shifting more of its focus to proteasome inhibitor carfilzomib.